HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the company's credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain.
The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an "area under the curve" (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. The AUC rose to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. The company holds over 20 issued patents related to technology enablement. For details on the intended use of its technology, refer to the company's Cleared Indications for Use.
This study is significant because it suggests that a portable, credit card-sized device could potentially help identify heart attack risk quickly and accurately, even outside of a hospital setting. For patients experiencing chest pain, timely detection of a heart attack is critical for survival and minimizing heart damage. The ability to use a personal baseline ECG for comparison could further improve accuracy, offering a more personalized approach to cardiac risk assessment.
The implications for the healthcare industry could be substantial. If the HeartBeam System gains FDA clearance for heart attack detection, it could enable emergency medical services, urgent care clinics, and even patients at home to perform rapid, reliable ECG assessments. This could reduce the time to diagnosis and treatment, potentially saving lives and reducing healthcare costs associated with unnecessary hospital visits or delayed care.
Investors and the broader medical community are watching these developments closely. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. For the full press release, visit https://ibn.fm/ainxV.
